FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006084386> ?p ?o ?g. }

• W2006084386 endingPage "1070" @default.
• W2006084386 startingPage "1064" @default.
• W2006084386 abstract "Medicare and third-party payers may be reluctant to pay for investigational (protocol) therapy for patients with cancer on the premise that such treatment is more expensive than standard therapy. However, prior studies that have attempted to compare protocol therapy with standard therapy have been difficult to interpret because of the assortment of malignancies studied and the lack of suitable control groups of patients who received standard therapy.In the current study, the authors conducted a retrospective review of the financial charges associated with protocol or nonprotocol (standard) chemotherapy in patients with a single malignancy, newly diagnosed acute myelogenous leukemia (AML), who received their initial course of chemotherapy (induction) at the Memorial Sloan-Kettering Cancer Center (MSKCC) between 1996 and 1999. Protocol and nonprotocol groups were analyzed according to clinical characteristics and standard prognostic features to determine whether the two groups were comparable. Median charges for all patients were determined using a database that linked clinical information, financial data, and clinical outcomes.A total of 353 patients with newly diagnosed AML were registered at MSKCC during the time period studied; of these, 79 patients (22%) received all of their care at the institution. Thirty patients (38%) received treatment on an investigational protocol. Forty-nine patients (62%) did not receive protocol therapy for the following reasons: 10 patients (20%) did not meet eligibility criteria, 4 patients (8%) were eligible for protocol therapy but declined, and 35 patients (71%) met protocol criteria but were not offered protocol therapy based on the judgment of their primary oncologist. The groups were not comparable because patients treated with standard therapy were older and had a poorer initial Eastern Cooperative Oncology Group (ECOG) performance status. Overall median charges for patients in the nonprotocol group were higher than for patients treated on a protocol although charges were not related to age, initial ECOG performance status, or cytogenetic risk group.Although charges for the nonprotocol group were higher, specific factors responsible for this difference were not identified. This study emphasizes the problems inherent in assembling suitable groups of patients for comparison." @default.
• W2006084386 created "2016-06-24" @default.
• W2006084386 creator A5003194414 @default.
• W2006084386 creator A5005743560 @default.
• W2006084386 creator A5031035765 @default.
• W2006084386 creator A5064065248 @default.
• W2006084386 creator A5079376081 @default.
• W2006084386 date "2002-08-19" @default.
• W2006084386 modified "2023-09-26" @default.
• W2006084386 title "Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy" @default.
• W2006084386 cites W1919339218 @default.
• W2006084386 cites W2114420812 @default.
• W2006084386 cites W2224360697 @default.
• W2006084386 doi "https://doi.org/10.1002/cncr.10805" @default.
• W2006084386 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12209692" @default.
• W2006084386 hasPublicationYear "2002" @default.
• W2006084386 type Work @default.
• W2006084386 sameAs 2006084386 @default.
• W2006084386 citedByCount "5" @default.
• W2006084386 countsByYear W20060843862014 @default.
• W2006084386 countsByYear W20060843862015 @default.
• W2006084386 crossrefType "journal-article" @default.
• W2006084386 hasAuthorship W2006084386A5003194414 @default.
• W2006084386 hasAuthorship W2006084386A5005743560 @default.
• W2006084386 hasAuthorship W2006084386A5031035765 @default.
• W2006084386 hasAuthorship W2006084386A5064065248 @default.
• W2006084386 hasAuthorship W2006084386A5079376081 @default.
• W2006084386 hasConcept C121608353 @default.
• W2006084386 hasConcept C126322002 @default.
• W2006084386 hasConcept C141071460 @default.
• W2006084386 hasConcept C142724271 @default.
• W2006084386 hasConcept C204787440 @default.
• W2006084386 hasConcept C2776694085 @default.
• W2006084386 hasConcept C2779399171 @default.
• W2006084386 hasConcept C2780385302 @default.
• W2006084386 hasConcept C71924100 @default.
• W2006084386 hasConceptScore W2006084386C121608353 @default.
• W2006084386 hasConceptScore W2006084386C126322002 @default.
• W2006084386 hasConceptScore W2006084386C141071460 @default.
• W2006084386 hasConceptScore W2006084386C142724271 @default.
• W2006084386 hasConceptScore W2006084386C204787440 @default.
• W2006084386 hasConceptScore W2006084386C2776694085 @default.
• W2006084386 hasConceptScore W2006084386C2779399171 @default.
• W2006084386 hasConceptScore W2006084386C2780385302 @default.
• W2006084386 hasConceptScore W2006084386C71924100 @default.
• W2006084386 hasIssue "5" @default.
• W2006084386 hasLocation W20060843861 @default.
• W2006084386 hasLocation W20060843862 @default.
• W2006084386 hasOpenAccess W2006084386 @default.
• W2006084386 hasPrimaryLocation W20060843861 @default.
• W2006084386 hasRelatedWork W2002120878 @default.
• W2006084386 hasRelatedWork W2003938723 @default.
• W2006084386 hasRelatedWork W2047967234 @default.
• W2006084386 hasRelatedWork W2118496982 @default.
• W2006084386 hasRelatedWork W2364998975 @default.
• W2006084386 hasRelatedWork W2369162477 @default.
• W2006084386 hasRelatedWork W2439875401 @default.
• W2006084386 hasRelatedWork W4238867864 @default.
• W2006084386 hasRelatedWork W2519357708 @default.
• W2006084386 hasRelatedWork W2525756941 @default.
• W2006084386 hasVolume "95" @default.
• W2006084386 isParatext "false" @default.
• W2006084386 isRetracted "false" @default.
• W2006084386 magId "2006084386" @default.
• W2006084386 workType "article" @default.